Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Anlotinib in Platinum-resistant Ovarian Cancer
NCT04376073Phase 2Unknown
- Start
- May 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib and anlotinib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC). Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
niraparibanlotinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04376073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04376073.